Nyashadzaishe Mafirakureva1, Star Khoza2, David A Mvere3, McLeod E Chitiyo3, Maarten J Postma4, Marinus Van Hulst5. 1. Unit of Pharmaco-Epidemiology & Pharmaco-Economics (PE2), Department of Pharmacy, University of Groningen, Groningen, The Netherlands National Blood Service Zimbabwe, Harare, Zimbabwe. 2. Department of Clinical Pharmacology, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe. 3. National Blood Service Zimbabwe, Harare, Zimbabwe. 4. Unit of Pharmaco-Epidemiology & Pharmaco-Economics (PE2), Department of Pharmacy, University of Groningen, Groningen, The Netherlands. 5. Unit of Pharmaco-Epidemiology & Pharmaco-Economics (PE2), Department of Pharmacy, University of Groningen, Groningen, The Netherlands Department of Clinical Pharmacy and Toxicology, Martini Hospital, Groningen, The Netherlands.
Abstract
BACKGROUND: Haemovigilance hinges on a systematically structured reporting system, which unfortunately does not always exist in resource-limited settings. We determined the incidence and pattern of transfusion-related adverse events reported to the National Blood Service Zimbabwe. MATERIALS AND METHODS: A retrospective review of the transfusion-event records of the National Blood Service Zimbabwe was conducted covering the period from 1 January 1999 to 31 December 2011. All transfusion-related event reports received during the period were analysed. RESULTS: A total of 308 transfusion adverse events (0.046%) were reported for 670,625 blood components distributed. The majority (61.6%) of the patients who experienced an adverse event were female. The median age was 36 years (range, 1-89 years). The majority (68.8%) of the adverse events were acute transfusion reactions consisting of febrile non-haemolytic transfusion reactions (58.5%), minor allergies (31.6%), haemolytic reactions (5.2%), severe allergic reactions (2.4%), anaphylaxis (1.4%) and hypotension (0.9%). Two-thirds (66.6%) of the adverse events occurred following administration of whole blood, although only 10.6% of the blood was distributed as whole blood. Packed cells, which accounted for 75% of blood components distributed, were associated with 20.1% of the events. DISCUSSION: The incidence of suspected transfusion adverse events was generally lower than the incidences reported globally in countries with well-established haemovigilance systems. The administration of whole blood was disproportionately associated with transfusion adverse events. The pattern of the transfusion adverse events reported here highlights the probable differences in practice between different settings. Under-reporting of transfusion events is rife in passive reporting systems.
BACKGROUND: Haemovigilance hinges on a systematically structured reporting system, which unfortunately does not always exist in resource-limited settings. We determined the incidence and pattern of transfusion-related adverse events reported to the National Blood Service Zimbabwe. MATERIALS AND METHODS: A retrospective review of the transfusion-event records of the National Blood Service Zimbabwe was conducted covering the period from 1 January 1999 to 31 December 2011. All transfusion-related event reports received during the period were analysed. RESULTS: A total of 308 transfusion adverse events (0.046%) were reported for 670,625 blood components distributed. The majority (61.6%) of the patients who experienced an adverse event were female. The median age was 36 years (range, 1-89 years). The majority (68.8%) of the adverse events were acute transfusion reactions consisting of febrile non-haemolytic transfusion reactions (58.5%), minor allergies (31.6%), haemolytic reactions (5.2%), severe allergic reactions (2.4%), anaphylaxis (1.4%) and hypotension (0.9%). Two-thirds (66.6%) of the adverse events occurred following administration of whole blood, although only 10.6% of the blood was distributed as whole blood. Packed cells, which accounted for 75% of blood components distributed, were associated with 20.1% of the events. DISCUSSION: The incidence of suspected transfusion adverse events was generally lower than the incidences reported globally in countries with well-established haemovigilance systems. The administration of whole blood was disproportionately associated with transfusion adverse events. The pattern of the transfusion adverse events reported here highlights the probable differences in practice between different settings. Under-reporting of transfusion events is rife in passive reporting systems.
Authors: S Imoto; K Kawamura; Y Tokumine; N Araki; S Akita; C Nishimura; H Inaba; K Saigo; O Mabuchi; H Okazaki Journal: Transfus Med Date: 2009-10-30 Impact factor: 2.019
Authors: Karen E King; R Sue Shirey; Sandra K Thoman; Debra Bensen-Kennedy; Warren S Tanz; Paul M Ness Journal: Transfusion Date: 2004-01 Impact factor: 3.157
Authors: Nyashadzaishe Mafirakureva; Star Khoza; Oliver Hassall; Brian E Faragher; Isaac Kajja; David A Mvere; Jean C Emmanuel; Maarten J Postma; Marinus van Hulst Journal: Blood Transfus Date: 2015-07-15 Impact factor: 3.443
Authors: Chris Edens; Kathryn A Haass; Melissa Cumming; Anthony Osinski; Lynne O'Hearn; Kelly Passanisi; Lynn Eaton; Paul Visintainer; Alexandra Savinkina; Matthew J Kuehnert; Sridhar V Basavaraju; Chester Andrzejewski Journal: Transfusion Date: 2018-11-14 Impact factor: 3.157
Authors: Kunal J Ghataliya; Jigar D Kapadia; Mira K Desai; K M Mehariya; G H Rathod; Nidhi Bhatnagar; M D Gajjar Journal: Asian J Transfus Sci Date: 2017 Jul-Dec